Novel Human Cell Lines for the Study of Primary Immunodeficiencies
Novel Human Cell Lines for the Study of Primary Immunodeficiencies
批准号:
7771176
负责人:
ERIC A HENDRICKSON
金额:
$22.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-01 至 2012-04-30
关键词:
AffectAmericanAreaBiological AssayBiological ModelsCell Culture SystemCell LineClinicDNADNA Double Strand BreakDNA RepairDNA Repair GeneDevelopmentDiagnosisDiseaseDouble Strand Break RepairEvolutionGene RearrangementGenesGenetic PolymorphismGenetic RecombinationGenome StabilityGrantHumanHuman Cell LineHuman DevelopmentImmuneImmune systemImmunoglobulin Class SwitchingImmunoglobulin Somatic HypermutationImmunoglobulin Switch RecombinationImmunologic Deficiency SyndromesIndividualLive BirthMetabolic PathwayMissionMutagenesisMutateMutationPathologyPatientsProcessReactionReagentRecombinant adeno-associated virus (rAAV)Research PersonnelSignal TransductionSiteSomatic CellSomatic Cell GeneticsStructureSymptomsSystemTelomere MaintenanceTherapeutic InterventionTherapeutic StudiesUnited States National Institutes of HealthV(D)J RecombinationVariantgenetically modified cellsmutantnovelpre-clinicalpublic health relevanceresearch studytissue culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We propose to develop a human somatic tissue culture model system that can be used to identify and characterize mutations in genes that cause PIDs (primary immune deficiencies). In this application we demonstrate that this approach can be used to provide a structure:function understanding of the DNA repair genes that regulate V(D)J {variable(diversity)joining} recombination, CSR (class switch recombination) and SHM (somatic hypermutation). V(D)J recombination and CSR are site-specific DNA rearrangement processes absolutely required for the development of the human immune system. SHM utilizes a non-essential DNA mutagenesis process that evolution has conscripted in a positive fashion to increase the efficacy of the immune system. Over the past decade it has been demonstrated that patients with mutations in any of about a dozen genes, most of them DNA DSB (double-strand break) repair genes, which are required for either one or all of these processes, result in PIDs when mutated. Importantly, most of these genes have functions outside of the immune system (e.g., signaling, genomic stability, and telomere maintenance) and it is not always clear which human symptoms/pathologies are associated with which activity of the gene, rendering therapeutic intervention difficult and even potentially dangerous. We have developed over the past several years a system using rAAV (recombinant adeno-associated virus) where targeted mutations can be made in virtually any human gene and in virtually any human cell line. We have used this system - in proof-of-principle experiments - to make human cell lines null for a number of PID-causative genes. In addition, we have spent several decades acquiring reagents, assays and expertise in a veritable bevy of areas relevant to DNA repair, V(D)J, CSR, SHM and telomere maintenance. By introducing either wild-type cDNAs or cDNAs containing human mutations into these genetically modified cell lines the impact of patient mutations on each metabolic pathway can be accurately assessed. These experiments should enhance our understanding of the basic domains and activities of these genes. In addition, it is reasonable to anticipate that the information generated from this study (i.e., a correlation of patient mutations to activity) can be productively used in the clinic to treat and/or diagnose PIDs. We believe that our proposal has a number of important general strengths: 1) it can in principle be used for any of the 120+ genes that - when mutated - are known to cause PIDs, 2) it can be used with any human somatic cell line of the researcher's choosing, 3) it allows for a rigorous assessment of whether a naturally occurring sequence variant is an inconsequential polymorphism or a debilitating mutation, 4) it permits a detailed structure:function analysis of the gene under study and 5) it provides novel cell lines that can be used for pre-clinical therapeutic studies.
PUBLIC HEALTH RELEVANCE: Project Narrative: Hendrickson Primary immune deficiencies currently affect ~500,000 Americans and newly affected individuals are accruing at the rate of 1 per 1,200 live births. This disease is genetically very heterogeneous with over 120 disease-causing genes correlated with over 200 clinically distinct types of immune deficiencies. Here we propose to develop a human somatic cell culture system in which we can characterize the great bulk of these genes and their relevant activities. The development of such a system has the ability to yield better therapies and is thus clearly relevant to the mission of NIH.)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
POLQ- and CtIP-regulated telomere fusions and translocations are involved in early events in carcinogenesis
-
批准号:10770273
-
项目类别:
-
资助金额:$29.45万
-
财政年份:2022
-
负责人:ERIC A HENDRICKSON
-
依托单位:
POLQ- and CtIP-regulated telomere fusions and translocations are involved in early events in carcinogenesis
-
批准号:10673149
-
项目类别:
-
资助金额:$49.95万
-
财政年份:2022
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ligase III regulates survival from crisis induced by gradual telomere shortening
-
批准号:9114537
-
项目类别:
-
资助金额:$33.52万
-
财政年份:2015
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ligase III regulates survival from crisis induced by gradual telomere shortening
-
批准号:9308903
-
项目类别:
-
资助金额:$33.52万
-
财政年份:2015
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku regulates non-homologous end joining pathways in human somatic cells
-
批准号:8298501
-
项目类别:
-
资助金额:$30.73万
-
财政年份:2011
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku regulates non-homologous end joining pathways in human somatic cells
-
批准号:8527889
-
项目类别:
-
资助金额:$1.55万
-
财政年份:2011
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku regulates non-homologous end joining pathways in human somatic cells
-
批准号:8658400
-
项目类别:
-
资助金额:$29.77万
-
财政年份:2011
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku regulates non-homologous end joining pathways in human somatic cells
-
批准号:8820471
-
项目类别:
-
资助金额:$1.89万
-
财政年份:2011
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku regulates non-homologous end joining pathways in human somatic cells
-
批准号:8193446
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2011
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku regulates non-homologous end joining pathways in human somatic cells
-
批准号:8649877
-
项目类别:
-
资助金额:$1.83万
-
财政年份:2011
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku regulates non-homologous end joining pathways in human somatic cells
-
批准号:8460914
-
项目类别:
-
资助金额:$28.87万
-
财政年份:2011
-
负责人:ERIC A HENDRICKSON
-
依托单位:
DNA Double-Strand Break Repair Regulates rAAV-Mediated Gene Targeting
-
批准号:8434196
-
项目类别:
-
资助金额:$27.38万
-
财政年份:2010
-
负责人:ERIC A HENDRICKSON
-
依托单位:
DNA Double-Strand Break Repair Regulates rAAV-Mediated Gene Targeting
-
批准号:7779935
-
项目类别:
-
资助金额:$28.66万
-
财政年份:2010
-
负责人:ERIC A HENDRICKSON
-
依托单位:
DNA Double-Strand Break Repair Regulates rAAV-Mediated Gene Targeting
-
批准号:8233524
-
项目类别:
-
资助金额:$28.37万
-
财政年份:2010
-
负责人:ERIC A HENDRICKSON
-
依托单位:
DNA Double-Strand Break Repair Regulates rAAV-Mediated Gene Targeting
-
批准号:8045508
-
项目类别:
-
资助金额:$28.37万
-
财政年份:2010
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Novel Human Cell Lines for the Study of Primary Immunodeficiencies
-
批准号:8067817
-
项目类别:
-
资助金额:$18.4万
-
财政年份:2010
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku86 Controls DNA Repair, Telomeres & Genomic Stability
-
批准号:7212192
-
项目类别:
-
资助金额:$23.93万
-
财政年份:2005
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku86 Controls DNA Repair, Telomeres & Genomic Stability
-
批准号:7391189
-
项目类别:
-
资助金额:$23.9万
-
财政年份:2005
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku86 Controls DNA Repair, Telomeres & Genomic Stability
-
批准号:6921119
-
项目类别:
-
资助金额:$25.08万
-
财政年份:2005
-
负责人:ERIC A HENDRICKSON
-
依托单位:
Ku86 Controls DNA Repair, Telomeres & Genomic Stability
-
批准号:7026451
-
项目类别:
-
资助金额:$24.67万
-
财政年份:2005
-
负责人:ERIC A HENDRICKSON
-
依托单位:
海外基金